Isotopic Labeling of the Tyrosine Kinase Inhibitor Binimetinib with Fluorine-18 and Preclinical Evaluation

The Ras-Raf-MEK-ERK signaling pathway is involved in numerous cancers. Monitoring its overactivation by PET imaging remains challenging, yet it holds significant potential for personalized diagnostics. Here, we report the fluorine-18 isotopic radiolabeling of binimetinib, an FDA-approved specific allosteric MEK1/2 inhibitor, for the treatment of BRAF-positive melanoma. The inherent structure of binimetinib makes its radiolabeling a strong challenge, addressed by evaluating seven precursors using a simplified model compound. A fully automated, four-step, one-pot radiosynthesis afforded [18F]binimetinib with a 9 ± 5% radiochemical yield after 100 min with >95% radiochemical purity. In vitro evaluation of [18F]binimetinib demonstrated specific uptake in H358 cells with activated Ras-Raf-MEK-ERK. PET imaging of an H358 xenograft mouse model revealed promising tumor uptake at 4 h post-injection with 1.96 ± 0.51 % ID.cm−3 in the tumor. This study provides insight into the in vivo pharmacokinetic profile derived from PET imaging of [18F]binimetinib and its potential for investigating MEK target availability in tumors.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-19
DOI
https://doi.org/10.1021/acs.jmedchem.6c02001
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Isotopic Labeling of the Tyrosine Kinase Inhibitor Binimetinib with Fluorine-18 and Preclinical Evaluation

Simon Specklin, Bertrand Kühnast, Charles Truillet, Caroline Denis et al.
Journal of Medicinal Chemistry
Radiopharmaceutical Chemistry and Applications
article

Isotopic Labeling of the Tyrosine Kinase Inhibitor Binimetinib with Fluorine-18 and Preclinical Evaluation

Simon Specklin, Bertrand Kühnast, Charles Truillet, Caroline Denis, Rémi Pelletier, Benoit Jégo
article en

Abstract

The Ras-Raf-MEK-ERK signaling pathway is involved in numerous cancers. Monitoring its overactivation by PET imaging remains challenging, yet it holds significant potential for personalized diagnostics. Here, we report the fluorine-18 isotopic radiolabeling of binimetinib, an FDA-approved specific allosteric MEK1/2 inhibitor, for the treatment of BRAF-positive melanoma. The inherent structure of binimetinib makes its radiolabeling a strong challenge, addressed by evaluating seven precursors using a simplified model compound. A fully automated, four-step, one-pot radiosynthesis afforded [18F]binimetinib with a 9 ± 5% radiochemical yield after 100 min with >95% radiochemical purity. In vitro evaluation of [18F]binimetinib demonstrated specific uptake in H358 cells with activated Ras-Raf-MEK-ERK. PET imaging of an H358 xenograft mouse model revealed promising tumor uptake at 4 h post-injection with 1.96 ± 0.51 % ID.cm−3 in the tumor. This study provides insight into the in vivo pharmacokinetic profile derived from PET imaging of [18F]binimetinib and its potential for investigating MEK target availability in tumors.

Journal of Medicinal Chemistry
Université Paris-Saclay (FR), Institut des Sciences des Plantes de Paris Saclay (FR)
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon